Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 3
1976 2
1977 5
1978 3
1979 9
1980 6
1981 19
1982 26
1983 28
1984 31
1985 60
1986 70
1987 52
1988 50
1989 103
1990 114
1991 127
1992 106
1993 141
1994 187
1995 223
1996 257
1997 329
1998 348
1999 326
2000 423
2001 421
2002 543
2003 537
2004 588
2005 610
2006 641
2007 647
2008 691
2009 713
2010 786
2011 812
2012 844
2013 845
2014 892
2015 946
2016 952
2017 964
2018 1004
2019 1066
2020 1152
2021 1243
2022 1274
2023 1295
2024 439

Text availability

Article attribute

Article type

Publication date

Search Results

20,859 results

Results by year

Filters applied: . Clear all
Page 1
Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.
Boxer AL, Sperling R. Boxer AL, et al. Cell. 2023 Oct 26;186(22):4757-4772. doi: 10.1016/j.cell.2023.09.023. Epub 2023 Oct 16. Cell. 2023. PMID: 37848035 Free article. Review.
Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Abeta antibodies lecanemab and donanemab. ...Moving forward, the challenge will be to develop more efficacious therapies with greater efficiency. Novel t …
Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Abeta antibodies …
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.
Kurkinen M. Kurkinen M. Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379. Adv Clin Exp Med. 2023. PMID: 37676096 Free article. Review.
Food and Drug Administration (FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical trials, lecanemab reduced amyloid in the brain and slowed cognitive decline. Here, I review in detail the clinical trial by …
Food and Drug Administration (FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical …
Systemic inflammatory regulators and risk of Alzheimer's disease: a bidirectional Mendelian-randomization study.
Yeung CHC, Schooling CM. Yeung CHC, et al. Int J Epidemiol. 2021 Jul 9;50(3):829-840. doi: 10.1093/ije/dyaa241. Int J Epidemiol. 2021. PMID: 33313759
This study aims to assess the effect of systemic inflammatory regulators on Alzheimer's disease within a bidirectional Mendelian-randomization design. METHODS: Genetic associations with Alzheimer's disease were obtained from the largest and most up-to-date genome-wide asso …
This study aims to assess the effect of systemic inflammatory regulators on Alzheimer's disease within a bidirectional Mendelian-randomiz …
Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
Avgerinos KI, Ferrucci L, Kapogiannis D. Avgerinos KI, et al. Ageing Res Rev. 2021 Jul;68:101339. doi: 10.1016/j.arr.2021.101339. Epub 2021 Apr 5. Ageing Res Rev. 2021. PMID: 33831607 Free PMC article. Review.
METHODS: Pubmed, Web of Science, ClinicalTrials.gov and gray literature were searched for phase III RCTs and random-effects meta-analyses were performed. RESULTS: Seventeen studies (12,585 patients) were included. ...Bapineuzumab, Gantenerumab and Crenezumab did not improv …
METHODS: Pubmed, Web of Science, ClinicalTrials.gov and gray literature were searched for phase III RCTs and random-effects meta-anal …
Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review.
Coley N, Giulioli C, Aisen PS, Vellas B, Andrieu S. Coley N, et al. Ageing Res Rev. 2022 Dec;82:101777. doi: 10.1016/j.arr.2022.101777. Epub 2022 Nov 4. Ageing Res Rev. 2022. PMID: 36336171 Free article. Review.
Recent methodological shifts concern target populations, primary outcome measures, and intervention design, but study design remains constant (parallel group randomised controlled trial). Future trials may consider using adaptive trials or interventions, and more ta …
Recent methodological shifts concern target populations, primary outcome measures, and intervention design, but study design remains constan …
Study protocol for the Alzheimer and music therapy study: An RCT to compare the efficacy of music therapy and physical activity on brain plasticity, depressive symptoms, and cognitive decline, in a population with and at risk for Alzheimer's disease.
Flo BK, Matziorinis AM, Skouras S, Sudmann TT, Gold C, Koelsch S. Flo BK, et al. PLoS One. 2022 Jun 30;17(6):e0270682. doi: 10.1371/journal.pone.0270682. eCollection 2022. PLoS One. 2022. PMID: 35771851 Free PMC article.
METHODS: One-hundred and thirty-five participants with memory complaints will be recruited for a parallel, three-arm Randomized Controlled Trial (RCT). Inclusion criteria are a diagnosis of mild (early) AD or mild cognitive impairment (MCI), or memory complaints wit …
METHODS: One-hundred and thirty-five participants with memory complaints will be recruited for a parallel, three-arm Randomized Contr …
Effectiveness of omega-3 fatty acid supplementation in patients with Alzheimer disease: A systematic review and meta-analysis.
Araya-Quintanilla F, Gutiérrez-Espinoza H, Sánchez-Montoya U, Muñoz-Yañez MJ, Baeza-Vergara A, Petersen-Yanjarí M, Fernández-Lecaros L. Araya-Quintanilla F, et al. Neurologia (Engl Ed). 2020 Mar;35(2):105-114. doi: 10.1016/j.nrl.2017.07.009. Epub 2017 Oct 4. Neurologia (Engl Ed). 2020. PMID: 28986068 Free article. English, Spanish.
INTRODUCTION: Alzheimer disease (AD) is a neurodegenerative disease characterised by progressive dementia associated with global cognitive dysfunction. METHODS: We conducted a systematic review and meta-analysis of clinical trials evaluating omega-3 supplemen …
INTRODUCTION: Alzheimer disease (AD) is a neurodegenerative disease characterised by progressive dementia associated with glob …
NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance.
Reading CL, Ahlem CN, Murphy MF. Reading CL, et al. Neurodegener Dis Manag. 2021 Aug;11(4):289-298. doi: 10.2217/nmt-2021-0022. Epub 2021 Jul 12. Neurodegener Dis Manag. 2021. PMID: 34251287 Free article.
Trial registration number: NCT04669028 (Clinicaltrials.gov). Lay abstract Diabetes and other inflammatory diseases increase the risk of Alzheimer's disease. ...NE3107 is an oral pharmaceutical that has been shown to decrease inflammation and to improve insulin function in …
Trial registration number: NCT04669028 (Clinicaltrials.gov). Lay abstract Diabetes and other inflammatory diseases increase the risk …
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Sperling RA, et al. Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351. Alzheimers Dement. 2011. PMID: 21784348 Free PMC article. Review.
Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amyloid-beta burden in Alzheimer's disease (AD). ...The workgroup proposes recommendations for the detection and monitoring of ARIA in ongoing …
Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amy …
Natural remedies for Alzheimer's disease: A systematic review of randomized controlled trials.
Ahmad S, Ahmed SB, Khan A, Wasim M, Tabassum S, Haider S, Ahmed F, Batool Z, Khaliq S, Rafiq H, Tikmani P, Gilani AU. Ahmad S, et al. Metab Brain Dis. 2023 Jan;38(1):17-44. doi: 10.1007/s11011-022-01063-9. Epub 2022 Aug 12. Metab Brain Dis. 2023. PMID: 35960461 Review.
A systematic search was conducted using Ovid MEDLINE, CINAHL, Cochrane and PubMed databases and reference lists up to November 30, 2021. Only randomized control trials were included and appraised using the National Institute of Health framework. ...
A systematic search was conducted using Ovid MEDLINE, CINAHL, Cochrane and PubMed databases and reference lists up to November 30, 2021. Onl …
20,859 results
You have reached the last available page of results. Please see the User Guide for more information.